Dermavant shows deepening effects of tapinarof on psoriasis ahead of FDA filing

Dermavant Sciences has linked its plaque psoriasis prospect tapinarof to deepening improvements in outcomes over the first year of treatment. The number of responders rose in an interim analysis of a 40-week extension study, which followed successful phase 3 clinical trials that read out last year.